glp 1 receptor agonist use and risk of suicide death New Study: GLP-1 Drugs Do Not Increase GLP-1 Receptor Agonists for the

DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect

### Competing Interest Statement ASK, AMM, MCG, JMD, CB, CL, SWB, DJL, PML, DRD, JMC, JPF, YL, ARS, DAT, DWP, SH, RBR, MSL, and DAG are employees and stockholders of Pfizer Inc

Ozempic (semaglutide) is a medication used to manage type 2 diabetes

CMSs efforts to expand Medicare coverage of GLP-1s for obesity could provide substantial benefits to millions of Medicare beneficiaries, given the potential demand for these highly effective medicationsThere are potential drawbacks to the short-term program, however.

We also describe the development of incretin-based pharmacotherapy, starting with exendin- 4 and ending with the identification of multi-incretin hormone receptor agonists, which appear to be the next major step in the fight against T2DM and obesity

Allulose is a rare sugar that may modestly support GLP-1 secretion through gut hormone pathways, but dietary changes alone rarely match the effect of prescription GLP-1 therapy